Kurowski M
Friedrich-Alexander-Universität Erlangen-Nürnberg, Institut für Pharmakologie und Toxikologie.
Z Rheumatol. 1988 Jan-Feb;47(1):37-42.
Four different formulations of diclofenac sodium, a widely used NSAID, were administered to eight healthy young volunteers in a cross-over study, according to a latin-square design. The subjects received either 75 mg as intramuscular injections or 150 mg as enteric-coated tablets. Following administration, blood samples were drawn and analysed for unchanged diclofenac, employing HPLC. 72.9% of the oral dose was absorbed with an average lag-time of 2.2 h. Peak plasma concentrations amounted to 2.9 micrograms/ml after 3.1 h, as compared to 2.15 micrograms/ml, 20-30 min following an intramuscular injection of 75 mg. Diclofenac sodium was excreted with an average half-life of 1.15 h. The bioavailability of the three i.m. injectable solutions, as calculated from the area under the curve (AUC), did not differ significantly. The results suggest that i.m. injectable diclofenac sodium provides fast drug liberation suitable for acute analgesic treatment, although the general risk of i.m. injections, as well as the very rare risk of protracted anaphylactic shocks, has to be taken into account. Despite the high variability of absorption, peak plasma concentrations and bioavailability, the enteric-coated tablets may be favourable in chronic antiinflammatory therapy.